Drug intelligence / Profile preview

TARN-D

Development stage: Preclinical
Lead developer: Tarn Biosciences
Modality: Small Molecules

Overview

TARN-D is a preclinical-stage small molecule being developed by Tarn Biosciences for the treatment of tuberculosis (TB) and non-tuberculous mycobacterial (NTM) infections. The drug is designed to target nitroreductase, an enzyme class within mycobacteria. In the context of mycobacterial therapy, nitroreductases are often involved in the metabolic activation of certain classes of antimicrobials or are essential for bacterial redox homeostasis. TARN-D represents a novel approach to addressing mycobacterial pathogens, including potentially drug-resistant strains, by modulating this specific enzymatic pathway.

Targets

DosRST (DosR-DosS-DosT two-component regulatory system)

Beyond the preview

Go deeper on TARN-D.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TARN-D.

Explore the full profile